Precision oncology is a beacon of hope for patients with cancer. And the clinical/economic need for earlier diagnosis and more effective treatments is driving technical innovation forward at a rapid pace.
If you’re interested in the latest efforts to translate novel technologies into the clinic for precision oncology, then this upcoming series is for you!
It will explore the implementation of novel technologies for clinically relevant information, the assessment of novel biomarkers for predictive and prognostic utility, and the current state of play for implementation strategies.
Register to the Empowering Precision Oncology webinar here
**Please note that by registering for one webinar in the series, you will automatically be registered to all subsequent webinars**
By registering to this series, you will:
- Gain an understanding of how long-read sequencing and methylation signatures can be applied for cancer diagnostics
- Hear about advances in non-invasive liquid biopsy diagnostics, hear success stories, strategic implementation and validation of these next-generation diagnostic tests
- Discover the advances and validation of liquid biopsies in a clinical setting, and the analytes of interest
- Learn about the challenges of implementation and how these are being overcome in a university hospital – with real case studies.
Webinar 3: A New Era of Long-Read Sequencing for Characterising Cancers
Thursday 24th October at 3pm BST / 10am EDT / 4pm CET
Long-read sequencing technologies have enabled us to identify and characterise complicated structural variants, understand methylation signatures, and could provide in-depth molecular characterisation at record speed.
This webinar will discuss the strengths of long-reads in a clinical setting with a case study example.
Somatic Variant Detection using Long-read Sequencing
- Mikhail Kolmogorov, Stadtman Investigator, National Cancer Institute
Somatic Structural Variant Detection Via Long-Read Sequencing In Paediatric Hematologic Malignancies
- Midhat Farooqi, Director of Molecular Oncology, Children’s Mercy Hospital
Webinar 1: Predictive, Prognostic & Novel Biomarkers for Precision Oncology
Thursday 10th October at 3pm BST / 10am EDT / 4pm
Large-panel comprehensive genomic profiling has made it possible to screen for pan-cancer biomarkers such as microsatellite instability, neurotrophic receptor kinases fusions and a high TMB. With a growing list of biomarkers, the utility of these to inform clinical decision-making can be pivotal to patient outcomes.
In this webinar, we will explore biomarkers that have the potential to impact patient care, when they might be most useful to guide decision-making, and how they can support difficult cases. You will be presented with clinical case studies and leave with a better understanding of how the biomarkers profiled and reported impact patient care.
Exploring and Testing Genomic Biomarkers for Pancreatic Cancer
- David Chang, Head of Therapeutic Development, The Glasgow Precision Oncology Laboratory and Reader in Surgery, The University of Glasgow
TARGET National; Bridging the Gap in Genomic Testing
- Zoulikha Zair, Medical Oncologist and Clinical Research Fellow, The Royal Marsden NHS Foundation Trust
Webinar 2: Liquid Biopsies for Precision Oncology
Thursday 17th October at 3pm BST / 10am EDT / 4pm CET
Liquid biopsies continue to inspire hope when it comes to transforming diagnostics. The advances in specificity and the analytes you can obtain from a sample has meant that liquid biopsies will increasingly become a standard of care for certain clinical scenarios.
This webinar will explore the ways in which liquid biopsies are being strategically implemented into the cancer care pathway and showcase examples of where they have proven critical for influencing patient outcomes. It will demonstrate where we are, and where we’re heading, to deliver on maximum patient impact using these tests.
Circulating Tumour Biomarker Testing in the NHS
- Michael Hubank, Head of Clinical Genomics (Research), The Royal Marsden NHS Foundation Trust
Innovations in Liquid Biopsy: Enhancing Purification with Magnetic Beads
- Karessa Garza, Scientist III, R&D, Sample Preparation, Thermo Fisher Scientific, Austin, TX, USA
Taking the U out of CUP: A cfDNA Methylation-Based Approach for the Detection of Tumour Tissue-of Origin in Cancers of Unknown Primary
- Alexandra Clipson, Deputy Lead of Nucleic Acids Biomarker Team, CRUK National Biomarker Centre
Webinar 4: How To – Strategically Implement Liquid Biopsies into Routine Clinical Care
Thursday 31st October at 3pm BST / 10am EDT / 4pm CET
This unique “How to” webinar will discuss the strategic implementation of liquid biopsies into routine care for patients with advanced cancer, complemented by clinical case studies.
You will leave this webinar with a better understanding of when, how, why and for whom liquid biopsies should be implemented. You will also receive advice on how to deal with major interpretation challenges such as:
- Understanding tumor fraction from plasma and how to measure it
- How to read a liquid biopsy report, with a special focus on interpreting variant allele frequencies (VAFs)
- What to expect with regards to technological limitations, or when the tests result in non-informative results
- Dealing with, for example, CHIP or potentially germline variants
- The critical role of the Molecular Tumor Board (MTB) in efficient use of ctDNA testing.
- And much more!
This walk-through will take you through the tried and tested methods of implementation, leaving you feeling better equipped for what is happening clinically as liquid biopsies become more mainstream.
Presented by: Samantha Hasenleithner, Scientific Officer, Medical University Graz
